QuidelOrtho Corp (QDEL) stock
QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3067% below fair value
$8.32−0.60 (-6.73%)
Close on Nov 20, 2026Market cap $570.55MP/E –Yield –
QuidelOrtho net income
Net income is the profit left for shareholders after every expense, interest and tax.
QuidelOrtho's net income for the twelve months ending Sep 27, 2026 was -$369.20M. For fiscal 2025 it was -$1.13B. The highest annual figure on record is $810.30M in fiscal 2020.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | -$1.13B | – |
| FY2024 | Dec 29, 2024 | -$2.05B | – |
| FY2023 | Dec 31, 2023 | -$10.10M | -101.8% |
| FY2022 | Jan 1, 2023 | $548.70M | -22.1% |
| FY2021 | Jan 2, 2022 | $704.20M | -13.1% |
| FY2020 | Jan 3, 2021 | $810.30M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | -$53.80M | – |
| Q2 FY2026 | Jun 28, 2026 | -$92.90M | – |
| Q1 FY2026 | Mar 29, 2026 | -$91.80M | – |
| Q4 FY2025 | Dec 28, 2025 | -$130.70M | – |
| Q3 FY2025 | Sep 28, 2025 | -$733.00M | – |
| Q2 FY2025 | Jun 29, 2025 | -$255.40M | – |
| Q1 FY2025 | Mar 30, 2025 | -$12.70M | – |
| Q4 FY2024 | Dec 29, 2024 | -$178.40M | -2648.6% |
| Q3 FY2024 | Sep 29, 2024 | -$19.90M | – |
| Q2 FY2024 | Jun 30, 2024 | -$147.70M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.71B | -3595.9% |
| Q4 FY2023 | Dec 31, 2023 | $7.00M | -76.9% |
| Q3 FY2023 | Oct 1, 2023 | -$12.70M | -166.1% |
| Q2 FY2023 | Jul 2, 2023 | -$53.20M | -375.6% |
| Q1 FY2023 | Apr 2, 2023 | $48.80M | -89.8% |
| Q4 FY2022 | Jan 1, 2023 | $30.30M | -89.6% |
| Q3 FY2022 | Oct 2, 2022 | $19.20M | -91.1% |
| Q2 FY2022 | Jul 3, 2022 | $19.30M | +1.0% |
| Q1 FY2022 | Apr 3, 2022 | $479.90M | +169.5% |
| Q4 FY2021 | Jan 2, 2022 | $291.30M | – |
| Q3 FY2021 | Oct 3, 2021 | $215.70M | – |
| Q2 FY2021 | Jul 4, 2021 | $19.10M | – |
| Q1 FY2021 | Apr 4, 2021 | $178.10M | – |
See a number that looks wrong?